

## Cephapirin / Prednisolone Formulation

Version 6.2      Revision Date: 04.12.2023      SDS Number: 764063-00017      Date of last issue: 30.09.2023  
Date of first issue: 16.06.2016

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Cephapirin / Prednisolone Formulation  
Other means of identification : Mastiplan (A011329)

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Veterinary product  
Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
20 Spartan Road  
1619 Spartan, South Africa  
Telephone : +27119239300  
E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

+1-908-423-6000

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Respiratory sensitisation, Category 1      H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Danger

Hazard statements : H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

## Cefapirin / Prednisolone Formulation

Version 6.2      Revision Date: 04.12.2023      SDS Number: 764063-00017      Date of last issue: 30.09.2023  
 Date of first issue: 16.06.2016

Precautionary statements : **Response:**  
 P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.  
 P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.

Hazardous components which must be listed on the label:  
 Cefapirin

**2.3 Other hazards**

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

**SECTION 3: Composition/information on ingredients****3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Cefapirin	21593-23-7 244-466-5	Resp. Sens. 1A; H334	>= 1 - < 10
prednisolone	50-24-8 200-021-7	Acute Tox. 4; H302 Repr. 2; H361d STOT RE 1; H372 (Bone marrow, Adrenal gland, Liver) Aquatic Chronic 2; H411	>= 0,25 - < 1

For explanation of abbreviations see section 16.

**SECTION 4: First aid measures****4.1 Description of first aid measures**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.  
 If not breathing, give artificial respiration.

## Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.2	04.12.2023	764063-00017	Date of first issue: 16.06.2016

---

- If breathing is difficult, give oxygen.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

### 4.2 Most important symptoms and effects, both acute and delayed

- Risks : May cause allergy or asthma symptoms or breathing difficulties if inhaled.
- Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).

### 4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.

---

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

- Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Metal oxides  
Silicon oxides

### 5.3 Advice for firefighters

- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

## Cephapirin / Prednisolone Formulation

Version 6.2      Revision Date: 04.12.2023      SDS Number: 764063-00017      Date of last issue: 30.09.2023  
Date of first issue: 16.06.2016

---

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

### SECTION 6: Accidental release measures

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

#### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

#### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

---

### SECTION 7: Handling and storage

#### 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.  
Local/Total ventilation : Use only with adequate ventilation.  
Advice on safe handling : Avoid breathing mist or vapours.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.

## Cephapirin / Prednisolone Formulation

Version 6.2      Revision Date: 04.12.2023      SDS Number: 764063-00017      Date of last issue: 30.09.2023  
Date of first issue: 16.06.2016

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.  
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**7.2 Conditions for safe storage, including any incompatibilities**

Requirements for storage areas and containers : Keep in properly labelled containers. Keep tightly closed.  
Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents  
Gases

**7.3 Specific end use(s)**

Specific use(s) : No data available

**SECTION 8: Exposure controls/personal protection****8.1 Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Zeolites	1318-02-1	OEL-RL (respirable dust fraction)	2 mg/m <sup>3</sup> (Aluminium)	ZA OEL
Further information: Occupational Exposure Limits - Restricted Limits For Hazardous Chemical Agents				
Cefapirin	21593-23-7	TWA	0.4 mg/m <sup>3</sup> (OEB 2)	Internal
Further information: RSEN				
prednisolone	50-24-8	TWA	10 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal

**8.2 Exposure controls****Engineering measures**

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

## Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.2	04.12.2023	764063-00017	Date of first issue: 16.06.2016

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

### Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection		
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Combined particulates and organic vapour type (A-P)

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

Appearance	:	liquid, oily
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available

**Cephapirin / Prednisolone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.2	04.12.2023	764063-00017	Date of first issue: 16.06.2016

---

Vapour pressure	:	No data available
Relative vapour density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

**9.2 Other information**

Flammability (liquids)	:	No data available
Molecular weight	:	No data available
Particle size	:	No data available

---

**SECTION 10: Stability and reactivity****10.1 Reactivity**

Not classified as a reactivity hazard.

**10.2 Chemical stability**

Stable under normal conditions.

**10.3 Possibility of hazardous reactions**

Hazardous reactions	:	Can react with strong oxidizing agents.
---------------------	---	---

**10.4 Conditions to avoid**

Conditions to avoid	:	None known.
---------------------	---	-------------

**10.5 Incompatible materials**

Materials to avoid	:	Oxidizing agents
--------------------	---	------------------

**10.6 Hazardous decomposition products**

No hazardous decomposition products are known.

**Cephapirin / Prednisolone Formulation**

Version 6.2      Revision Date: 04.12.2023      SDS Number: 764063-00017      Date of last issue: 30.09.2023  
Date of first issue: 16.06.2016

---

**SECTION 11: Toxicological information****11.1 Information on toxicological effects**

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Components:****Cefapirin:**

Acute oral toxicity : LD50 (Mouse): 26.000 mg/kg

Acute toxicity (other routes of administration) : LD50 (Mouse): > 7.600 mg/kg  
Application Route: Intraperitoneal

LD50 (Rat): 7.800 mg/kg  
Application Route: Intraperitoneal

**prednisolone:**

Acute oral toxicity : LD50 (Mouse): 1.680 mg/kg  
LD50 (Rat): > 3.857 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): 147 mg/kg  
Application Route: Subcutaneous

LD50 (Mouse): 767 mg/kg  
Application Route: Intraperitoneal

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****prednisolone:**

Remarks : No data available

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****prednisolone:**

Remarks : No data available



**Cephapirin / Prednisolone Formulation**

Version 6.2      Revision Date: 04.12.2023      SDS Number: 764063-00017      Date of last issue: 30.09.2023  
Date of first issue: 16.06.2016

---

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

**Components:****Cefapirin:**

Assessment : Probability or evidence of high respiratory sensitisation rate in humans

**prednisolone:**

Remarks : No data available

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Cefapirin:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

**prednisolone:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Mouse Lymphoma  
Result: negative

Test Type: sister chromatid exchange assay  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Rat  
Application Route: Oral  
Result: negative

Test Type: sister chromatid exchange assay  
Species: Humans  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****prednisolone:**

Species : Rat  
Application Route : Oral

## Cefapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.2	04.12.2023	764063-00017	Date of first issue: 16.06.2016

---

Exposure time : 18 Months  
Result : negative

**Reproductive toxicity**

Not classified based on available information.

**Components:****Cefapirin:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Intraperitoneal injection  
Fertility: LOAEL: > 500 mg/kg body weight  
Result: No effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intraperitoneal injection  
Developmental Toxicity: LOAEL: > 200 mg/kg body weight

**prednisolone:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Subcutaneous  
Fertility: NOAEL: 1 mg/kg body weight  
Result: No effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Oral  
Developmental Toxicity: LOAEL: 0,5 mg/kg body weight  
Result: Malformations were observed., Cleft palate

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: LOAEL: 30 mg/kg body weight  
Result: decreased blood formation

Species: Rat  
Application Route: Subcutaneous  
Developmental Toxicity: NOAEL: 25 mg/kg body weight  
Result: No effects on foetal development

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

Not classified based on available information.

## Cephapirin / Prednisolone Formulation

Version 6.2      Revision Date: 04.12.2023      SDS Number: 764063-00017      Date of last issue: 30.09.2023  
 Date of first issue: 16.06.2016

**Components:****prednisolone:**

Target Organs : Bone marrow, Adrenal gland, Liver  
 Assessment : Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Cefapirin:**

Species : Rat  
 LOAEL :  $\geq 200$  mg/kg  
 Application Route : Intraperitoneal  
 Target Organs : Blood  
 Remarks : anemia

Species : Dog  
 LOAEL : 20 mg/kg  
 Application Route : Oral  
 Exposure time : 4 Months  
 Target Organs : Gastrointestinal tract

Species : Dog  
 LOAEL : 100 mg/kg  
 Application Route : Intramuscular  
 Exposure time : 10 Months  
 Target Organs : Blood, Gastrointestinal tract  
 Remarks : anemia

**prednisolone:**

Species : Rat  
 LOAEL : 0,6 mg/kg  
 Application Route : Oral  
 Exposure time : 63 Days  
 Target Organs : Bone marrow

Species : Dog  
 LOAEL : 2,5 mg/kg  
 Application Route : Oral  
 Exposure time : 6 Weeks  
 Target Organs : Adrenal gland

Species : Rabbit  
 LOAEL : 1 mg/kg  
 Application Route : Oral  
 Exposure time : 24 Weeks  
 Target Organs : Liver

**Aspiration toxicity**

Not classified based on available information.

**Cephapirin / Prednisolone Formulation**

Version 6.2      Revision Date: 04.12.2023      SDS Number: 764063-00017      Date of last issue: 30.09.2023  
Date of first issue: 16.06.2016

---

**Experience with human exposure****Components:****Cefapirin:**

Ingestion : Symptoms: Nausea, Vomiting, Abdominal pain, Diarrhoea, vaginitis, colitis, anorexia, Rash, anaphylaxis

**prednisolone:**

Ingestion : Symptoms: sodium retention, Headache, Vertigo, fluid retention, subcutaneous bleeding, striae, skin atrophy, menstrual irregularities

---

**SECTION 12: Ecological information****12.1 Toxicity****Components:****prednisolone:**

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 85 mg/l  
Exposure time: 48 h

Toxicity to algae/aquatic plants : NOEC (Pseudokirchneriella subcapitata (green algae)): 160 mg/l  
Exposure time: 72 h

EC50 (Pseudokirchneriella subcapitata (green algae)): > 160 mg/l  
Exposure time: 72 h

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0,23 mg/l  
Exposure time: 7 d  
Species: Ceriodaphnia dubia (water flea)

**12.2 Persistence and degradability**

No data available

**12.3 Bioaccumulative potential****Components:****prednisolone:**

Partition coefficient: n-octanol/water : log Pow: 1,46

**12.4 Mobility in soil**

No data available

**12.5 Results of PBT and vPvB assessment****Product:**

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

## Cephapirin / Prednisolone Formulation

Version 6.2      Revision Date: 04.12.2023      SDS Number: 764063-00017      Date of last issue: 30.09.2023  
Date of first issue: 16.06.2016

---

### 12.6 Other adverse effects

**Product:**

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

## SECTION 14: Transport information

### 14.1 UN number

ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

### 14.2 UN proper shipping name

ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

### 14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

## Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.2	04.12.2023	764063-00017	Date of first issue: 16.06.2016

---

**14.4 Packing group**

<b>ADN</b>	:	Not regulated as a dangerous good
<b>ADR</b>	:	Not regulated as a dangerous good
<b>RID</b>	:	Not regulated as a dangerous good
<b>IMDG</b>	:	Not regulated as a dangerous good
<b>IATA (Cargo)</b>	:	Not regulated as a dangerous good
<b>IATA (Passenger)</b>	:	Not regulated as a dangerous good

**14.5 Environmental hazards**

Not regulated as a dangerous good

**14.6 Special precautions for user**

Not applicable

**14.7 Transport in bulk according to Annex II of Marpol and the IBC Code**

Remarks : Not applicable for product as supplied.

---

**SECTION 15: Regulatory information****15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

**The components of this product are reported in the following inventories:**

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

**15.2 Chemical safety assessment**

A Chemical Safety Assessment has not been carried out.

---

**SECTION 16: Other information**

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

**Full text of H-Statements**

H302	:	Harmful if swallowed.
H334	:	May cause allergy or asthma symptoms or breathing difficulties if inhaled.
H361d	:	Suspected of damaging the unborn child.
H372	:	Causes damage to organs through prolonged or repeated exposure.
H411	:	Toxic to aquatic life with long lasting effects.

**Full text of other abbreviations**

Acute Tox.	:	Acute toxicity
Aquatic Chronic	:	Long-term (chronic) aquatic hazard

## Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.2	04.12.2023	764063-00017	Date of first issue: 16.06.2016

Repr.	:	Reproductive toxicity
Resp. Sens.	:	Respiratory sensitisation
STOT RE	:	Specific target organ toxicity - repeated exposure
ZA OEL	:	South Africa. The Regulations for Hazardous Chemical Agents, Occupational Exposure Limits
ZA OEL / OEL-RL	:	Occupational Exposure Limit Restricted limit - 8- hour exposure or equivalent (12 hour shifts)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

**Classification of the mixture:**

Resp. Sens. 1                      H334

**Classification procedure:**

Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only

## Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.2	04.12.2023	764063-00017	Date of first issue: 16.06.2016

---

to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN